Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Clinical trial NCT03246685 · TERMINATED
Trial details
- NCT number
- NCT03246685
- Sponsor
- HiberCell, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-08
- Primary completion
- 2018-04-13
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.